Biosimilar Interleukins Market Size Forecasted To Achieve $20.79 Billion By 2029 With Steady Growth

The Biosimilar Interleukins Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Biosimilar Interleukins Market Size and Projected Growth Rate?
The biosimilar interleukins market has grown rapidly in recent years. It will increase from $3.9 billion in 2024 to $5.41 billion in 2025 at a compound annual growth rate (CAGR) of 39.0%. This growth is attributed to the rise in autoimmune diseases, greater awareness of biosimilar interleukins, enhanced government support for biosimilars, the expansion of the biosimilar market, and the increasing demand from patients.

The biosimilar interleukins market is forecast to grow exponentially, hitting $20.79 billion by 2029 with a CAGR of 40.0%. Contributing factors include expanding patient base, rising access to care, preference for personalized treatments, and less invasive options. Major trends include global collaborations, quality manufacturing, targeted immunotherapies, and technological advances in biosimilars.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3433

What Are the Major Segments in the Biosimilar Interleukins Market?
The biosimilar interleukins market covered in this report is segmented -

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

What Are The Driving Biosimilar Interleukins Market Evolution?
Increasing cases of autoimmune disorders such as psoriasis and rheumatoid arthritis are supporting the interleukin biosimilars market growth. These diseases result from immune system malfunctions, and interleukin-targeting biologics help manage them. The National Institutes of Health reported in February 2024 that global autoimmune disease incidence and prevalence are rising annually by 19.1% and 12.5% respectively, reinforcing market demand.

Which Firms Dominate The Biosimilar Interleukins Market Segments?
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

What Trends Are Driving Growth in The Biosimilar Interleukins Market?
Leading companies in the biosimilar interleukins market are developing new products, such as Tofidence (tocilizumab-bavi), to boost profitability. Tofidence, a monoclonal antibody targeting interleukin-6 receptors, is used to treat various inflammatory autoimmune disorders. In September 2023, Biogen received FDA approval for Tofidence as the first biosimilar to Genentech's Actemra. Tofidence is administered through intravenous infusion and is approved for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

Which Is The Largest Region In The Biosimilar Interleukins Market?
The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Biosimilar Interleukins Market?
2. What is the CAGR expected in the Biosimilar Interleukins Market?
3. What Are the Key Innovations Transforming the Biosimilar Interleukins Industry?
4. Which Region Is Leading the Biosimilar Interleukins Market?

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.